David Roblin BSc, MBBS

Dr David Roblin joined as our Chief Operating Officer and President of Research and Development in early 2017 and expanded his role to become Chief Medical Officer in May 2017. Dr Roblin has been acting as a research and development adviser to Summit since 2014.
Dr Roblin is an experienced scientist and physician, with a distinguished career in the pharmaceutical industry. He and his units have brought many medicines in several therapy areas through R&D to commercialisation, including in anti-infectives azithromycin, ciprofloxacin, moxifloxacin, voriconazole and maraviroc.
Dr Roblin has previously served as the Chief Operating Officer and Director of Scientific Translation at the Francis Crick Institute in London (2014 – 2017). Prior to this, he was Head of Research and Chief Medical Officer for Europe R&D at Pfizer Inc. from 2008 to 2011 and was Head of Therapy Area for Anti-infectives at Bayer AG from 1997 to 1999. He is also a non-executive director of Sosei PLC and sits on a variety of committees at Wellcome, on the UK Biomedical Catalyst Fund and the LEO Foundation prize committee.